Evidence map›Paper›PMID 28413453›Full record

ArticleGut pathogens2017

Amelioration of intestinal and systemic sequelae of murine

Ira Ekmekciu, Ulrike Fiebiger, Kerstin Stingl, Stefan Bereswill, Markus M Heimesaat

Open access · goldAbstract read
In one paragraph

Article in Gut pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025
    Review
  2. Article
  3. Article
  4. Anti-Foodborne pathogens and disease · 2022
    Review
  5. TheMicroorganisms · 2021
    Article
  6. Article
  7. Treatment with the Probiotic Product AviguardInternational journal of molecular sciences · 2021
    Article
  8. Article
  9. Anticolonization of Carbapenem-ResistantFrontiers in cellular and infection microbiology · 2021
    Article
  10. Article
  11. New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ira EkmekciuDepartment of Microbiology and Hygiene, Charité-University Medicine Berlin, CC5, Campus Benjamin Franklin, FEM, Garystr. 5, 14195 Berlin, Germany.
Ulrike FiebigerDepartment of Microbiology and Hygiene, Charité-University Medicine Berlin, CC5, Campus Benjamin Franklin, FEM, Garystr. 5, 14195 Berlin, Germany.
Kerstin StinglDepartment of Biological Safety, Federal Institute for Risk Assessment (BfR), National Reference Laboratory for Campylobacter, Berlin, Germany.
Stefan BereswillDepartment of Microbiology and Hygiene, Charité-University Medicine Berlin, CC5, Campus Benjamin Franklin, FEM, Garystr. 5, 14195 Berlin, Germany.
Markus M HeimesaatDepartment of Microbiology and Hygiene, Charité-University Medicine Berlin, CC5, Campus Benjamin Franklin, FEM, Garystr. 5, 14195 Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEFederal Institute for Risk Assessment · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence of human METHODS AND

resultsSecondary abiotic mice generated by broad-spectrum antibiotic treatment were perorally challenged with the commercial probiotic compound VSL#3 consisting of

conclusionAdministration of probiotic formulations such as VSL#3 might open up valuable strategies for prophylaxis and/or treatment of

Indexed as

Anti-inflammatory cytokinesApoptosisBacterial in vivo competitionExtra-intestinal and systemic sequelae of infectionGnotobiotic miceInnate and adaptive immune cellsPathogen–commensal bacteria–host interactionProbiotic compoundPro-inflammatory cytokinesSecondary abiotic miceVSL#3

Identifiers

PMID28413453
PMCPMC5387377
OpenAlexW2606419941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.